NCT05835466 2026-01-07
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
Clinical Trials
3 trialsNCT05212701 2024-04-30
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
Dompé Farmaceutici S.p.A
Phase 2 Withdrawn
NCT01861054 2021-05-14
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
Dompé Farmaceutici S.p.A
Phase 2 Terminated